DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Any EGFR TKI

DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - AfatinibПодробнее

Overview of the world of EGFR mutant lung cancersПодробнее

David Spigel, MD: Use of TKI Therapy in Patients with EGRF Exon 19 Deletion NSCLCПодробнее

TKI-resistant EGFR-mutant NSCLCПодробнее

Adjuvant therapy for EGFR mutant NSCLCПодробнее

What targeted therapies are used for people with the EGFR mutation?Подробнее

Jack West, MD: Use of TKI Therapy in Patients with EGRF Exon 19 Deletion NSCLCПодробнее

Deciphering the data in EGFR - Mutant NSCLCПодробнее

Advancing Care for Patients With EGFR Mutation–Positive NSCLC: Precision Medicine StrategiesПодробнее

Dr Ullas Batra | Dissecting Molecular differences between EGFR Exon 19 & 21 L858R mutationsПодробнее

Repeat biopsy in lung cancer patients with EGFR mutationПодробнее

EGFR mutation positive tumors: Treatment strategies in front line and at relapseПодробнее

Adjuvant EGFR-Targeted Therapy as a Game Changer in Multimodal NSCLC ManagementПодробнее

Patient Selection, Therapeutic Sequencing, & Treatment Selection in EGFR Mutation-Positive NSCLCПодробнее

EGFR-Mutant Lung Cancer: Initial ApproachПодробнее

EGFR Mutations in Patients With Lung CancerПодробнее

FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutationsПодробнее

Dr. Yu on Treatments for EGFR-Mutant Lung CancerПодробнее

EGFR Mutations in NSCLCПодробнее